
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown
3
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
4
Persistent Barriers Keep Oral HIV PrEP Out of Reach for High-Risk Groups
5














































